Figure 6.ANGPTL2 promotes tumor growth and lymphangiogenesis in vivo. (A–C) CL1-0 and CL1-5 cells were subcutaneously injected into the right flanks of BALB/c-nu mice. Four weeks later, the mice were sacrificed and the tumors were excised and weighed (n=5). (D) Tumor sections were immunostained using ANGPTL2, LYVE-1 and VEGF-A antibodies. *p < 0.05 compared with controls.
